M FLU

 A

Here’s a clean summary of the study you mentioned:

---

Timing of Influenza Antiviral Therapy and Risk of Death in Adults Hospitalized With Influenza-Associated Pneumonia

Source: Clinical Infectious Diseases, 2025 Feb 24; 80(2):461–468.
DOI: 10.1093/cid/ciae427
PMID: 39172994

---

Study Overview

• Data Source: FluSurv-NET (Influenza Hospitalization Surveillance Network), 2012–2019.

• Population: Adults hospitalized with influenza-associated pneumonia.

• Goal: Investigate the association between timing of antiviral treatment initiation (primarily oseltamivir) and mortality risk.

---

Key Findings

• Early antiviral therapy (within 2 days of symptom onset) was strongly associated with reduced risk of in-hospital death.

• Delayed antiviral initiation (>2 days after symptom onset) was linked with higher mortality.

• Even among patients severely ill at admission, earlier antiviral treatment conferred a survival benefit.

• Benefit persisted after adjusting for confounders (age, comorbidities, influenza subtype, illness severity).

---

Clinical Implications

• Start antivirals as early as possible in patients with suspected or confirmed influenza-associated pneumonia — ideally within 48 hours of symptom onset.

• Do not delay treatment while awaiting lab confirmation, especially during high influenza activity periods.

• Supports empiric antiviral use in hospitalized adults when influenza is suspected.

---

Quote from Authors

"Prompt initiation of influenza antiviral therapy remains a critical strategy to reduce mortality in adults hospitalized with influenza-associated pneumonia."

---

Would you like me to also make a quick 1-slide infographic summarizing this? 📊
It would be super handy for teaching, rounds, or sharing!